ScreenerHero

AIMAIM ImmunoTech Inc.

AMEX · US · Healthcare · Biotechnology · aimimmuno.com
0.2584USD+8.48%Mkt Cap: 7.87M $P/E: —

AIM ImmunoTech Inc., an immuno-pharma company, engages in the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap7.87M $
Enterprise Value1.82M $
Revenue (TTM)95.00K $
Gross Profit-40.00K $
Net Income (TTM)-13.96M $
Revenue/Share0.0140 USD
Last Price0.2584 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees19
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS00901B1052
Valuation
P/E (Trailing)—
P/E (Forward)-0.70
PEG0.71
EV/EBITDA-0.17
EV/Revenue19.19
P/S82.80
P/B0.97
EPS (TTM)-0.71
EPS (Forward)-0.37
52W Range
0.19013% of range2.890
52W High2.890 USD
52W Low0.1901 USD
Profitability
Gross Margin-45.45%
Oper. Margin-13511.54%
EBITDA Margin0.00%
Profit Margin-15861.36%
ROE142.68%
ROA-241.40%
Growth
Revenue Growth4.00%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.96M $
CapEx (TTM)378.00K $
FCF Margin-14800.53%
FCF Yield-178.74%
Net Debt-6.04M $
Net Debt/EBITDA0.56
Balance Sheet
Debt/Equity-0.50
Current Ratio2.11
Quick Ratio2.02
Book Value/Sh0.2670 USD
Cash/Share0.3270 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1031:1000
Split DateFeb 10, 2026
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)4.250 USD
Upside (mean)+1544.7%
Target Range1.500 USD – 7.000 USD
$1.500+1544.7% to mean$7.000
# Analysts2
Ownership
Shares Out.30.44M
Float27.69M
Insiders0.53%
Institutions3.88%
Short Interest
Short Ratio1.3d
Short % Float3.31%
Short % Out.3.30%
Shares Short913.89K
Short (prev mo.)2.20M
Technical
SMA 500.2898 (-10.8%)
SMA 2000.7724 (-66.5%)
Beta1.19
S&P 52W Chg19.18%
Avg Vol (30d)1.16M
Avg Vol (10d)1.18M
Technical Indicators
RSI (14)46.7
MACD-0.0182
MACD Signal-0.0221
MACD Hist.+0.0039
BB Upper0.2860 USD
BB Middle0.2538 USD
BB Lower0.2217 USD
BB Width25.34%
ATR (14)0.0337 USD
Vol Ratio (20d)0.60x